PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 15 | 3 | 119–123
Article title

Oczekiwania i potrzeby chorych w zakresie leczenia stwardnienia rozsianego a wyniki badania BENEFIT 11

Content
Title variants
EN
Expectations and needs of patients concerning the treatment of multiple sclerosis and the results of the BENEFIT 11 study
Languages of publication
EN PL
Abstracts
EN
The expectations and needs of patients concerning the treatment of multiple sclerosis focus on the improvement of chances for the pursuit of their life goals. The contemporary patient has an increasing amount of information on the indications for the use of different medicines. Therefore, the conclusions derived from the BENEFIT study summarised results, especially those concerning the last follow-up – after 11 years, have generated knowledge of vital importance to the patients. It was demonstrated that the patients who started their therapy earlier had a longer time to conversion to multiple sclerosis – by 2.7 years compared to the group with postponed treatment. The annualised relapse rate was significantly lower and the time to the next relapse was significantly longer in patients who received treatment early. Only 13.3% of individuals left employment immediately after they were diagnosed with multiple sclerosis and only 12.2% went on disability pension. The results of the BENEFIT 11 study, especially those relating to professional activity, support the idea of starting the treatment as early as possible and are important particularly to those patients for whom work is a value in itself. The knowledge derived from the BENEFIT 11 study that early interferon beta treatment provides a chance for maintaining professional activity, delays the conversion from the relapsing-remitting multiple sclerosis to the secondary progressive form of the disease and minimises the progression of disability, significantly affects the patient’s willingness to comply with the recommendations and treatment regimens, i.e. promotes patient adherence. This knowledge should also be the basis of communication with those individuals who will be diagnosed with multiple sclerosis and who will be asking questions about their future.
PL
Oczekiwania i potrzeby chorych związane z leczeniem stwardnienia rozsianego odnoszą się do poprawy szans na realizację założonych celów życiowych. Współczesny pacjent ma coraz więcej informacji na temat wskazań do stosowania poszczególnych preparatów. Dlatego wnioski z podsumowań wyników badania BENEFIT, a zwłaszcza ostatniej obserwacji – po 11 latach, przyniosły wiedzę mającą zasadnicze znaczenie dla chorych. Wykazano, że pacjenci, którzy wcześniej rozpoczęli terapię, wykazywali dłuższy czas konwersji do stwardnienia rozsianego – o 2,7 roku w porównaniu z grupą z odroczonym leczeniem. Wśród chorych wcześnie leczonych roczny wskaźnik rzutów był istotnie niższy, a czas do wystąpienia kolejnego rzutu – znamiennie dłuższy. Jedynie 13,3% osób zrezygnowało z pracy bezpośrednio po rozpoznaniu stwardnieniu rozsianego, a tylko 12,2% przeszło na rentę. Wyniki BENEFIT 11, zwłaszcza te odnoszące się do aktywności zawodowej, przekonują do jak najszybszego rozpoczęcia leczenia i są istotne szczególnie dla pacjentów, dla których praca stanowi wartość samą w sobie. Wynikająca z BENEFIT 11 wiedza o tym, że wczesne leczenie interferonem beta daje szansę na utrzymanie aktywności zawodowej, opóźnia konwersję z postaci rzutowo-remisyjnej do wtórnie przewlekle postępującej i minimalizuje postęp niepełnosprawności, znacząco wpływa na przekonanie chorego do przestrzegania zaleceń i schematów leczenia, czyli sprzyja adherencji. Wiedza ta powinna być także podstawą komunikacji z osobami, u których dopiero zostanie zdiagnozowane stwardnienie rozsiane i które będą pytać o swoją przyszłość.
Discipline
Publisher

Year
Volume
15
Issue
3
Pages
119–123
Physical description
Contributors
  • Zakład Psychologii Klinicznej i Psychoprofilaktyki, Instytut Psychologii, Uniwersytet Szczeciński, Szczecin, Polska, andrzej.potemkowski@wp.pl
References
  • Bakas T, Austin JK, Okonkwo KF et al.: Needs, concerns, strategies, and advice of stroke caregivers the first 6 months after discharge. J Neurosci Nurs 2002; 34: 242–251.
  • Benbow CL, Koopman WJ: Clinic-based needs assessment of individuals with multiple sclerosis and significant others: implications for program planning – psychological needs. Rehabil Nurs 2003; 28: 109–116.
  • Deeken JF, Taylor KL, Mangan P et al.: Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage 2003; 26: 922–953.
  • Edan G, Freedman M, Montalban X et al.: Long-term impact of early MS treatment with interferon beta-1b (IFNβ-1b): clinical, MRI, employment and patient-reported outcomes (PROs) at the 11-year follow-up of BENEFIT (BENEFIT 11). Presented at the American Academy of Neurology’s 67th Annual Meeting; April 18–25, 2015;
  • Washington, DC. Available from: http://www.neurology.org/content/84/14_Supplement/P7.012.short?rss=1.
  • Edan G, Kappos L, Montalban X et al.: Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2014; 85: 1183–1189.
  • Fraser RT, Clemmons DC, Bennett F: Multiple Sclerosis: Psychosocial and Vocational Interventions. Demos Medical Publishing, New York 2002.
  • Haase R, Schultheiss T, Kempcke R et al.: Modern communication technology skills of patients with multiple sclerosis. Mult Scler 2013; 19: 1240–1241.
  • Hay MC, Strathmann C, Lieber E et al.: Why patients go online: multiple sclerosis, the internet, and physician-patient communication. Neurologist 2008; 14: 374–381.
  • Kappos L, Edan G, Freedman MS et al.; BENEFIT Study Group: Clinical outcomes in patients with CIS treated with interferon beta-1b: 11-year follow-up of BENEFIT. Presented at the ACTRIMSECTRIMS Meeting, MS Boston 2014. P7.012.
  • Kappos L, Freedman MS, Polman CH et al.; BENEFIT Study Group: Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.
  • Kappos L, Freedman MS, Polman CH et al.; BENEFIT Study Group: Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009; 8: 987–997.
  • Kappos L, Polman CH, Freedman MS et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242–1249.
  • Koopman W: Needs assessment of persons with multiple sclerosis and significant others: using the literature review and focus groups for preliminary survey questionnaire development. Axone 2003; 24: 10–15.
  • Koopman WJ, Benbow CL, Vandervoort M: Top 10 needs of people with multiple sclerosis and their significant others. J Neurosci Nurs 2006; 38: 369–373.
  • Larocca N, Kalb R, Scheinberg L et al.: Factors associated with unemployment of patients with multiple sclerosis. J Chronic Dis 1985; 38: 203–210.
  • McQuay HJ, Moore AR: Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997; 126: 712–720.
  • Miltenburger C, Kobelt G: Quality of life and cost of multiple sclerosis. Clin Neurol Neurosurg 2002; 104: 272–275.
  • Pierce LL, Gordon M, Steiner V: Families dealing with stroke desire information about self-care needs. Rehabil Nurs 2004; 29: 14–17.
  • Roessler R, Rumrill P, Hennessey M: Employment Concerns of People with Multiple Sclerosis: Building a National Employment Agenda. Report Submitted to the National Multiple Sclerosis Society. Kent State University Center for Disability Studies, Kent, OH 2002.
  • Roessler RT, Rumrill PD, Fitzgerald SM: Predictors of employment status for people with multiple sclerosis. Rehabil Couns Bull 2004; 47: 96–103.
  • Rumrill P: Help to stay at work: vocational rehabilitation strategies for people with multiple sclerosis. Mult Scler Foc 2006; 7: 14–18.
  • Sato A, Ricks K, Watkins S: Needs of caregivers of clients with multiple sclerosis. J Community Health Nurs 1996; 13: 31–42.
Document Type
review
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-377438ac-714d-4b13-84d7-8cc5d88e8d3b
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.